Evidence map›Paper›PMID 42430191›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Proteome-Wide Target Identification Using Reactive Metallo-Scaffolds (r-mS): A Platform for Metallodrug Discovery.

Jessica E Waters, Harry Wilders, George S Biggs, Mika Kintzel, Emma E Cawood, Jonathan Bailey, Sarah Maslen, Yew Mun Yip, Mason Wakley, Ioannis G Riziotis and 6 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jessica E WatersThe Biological Inorganic Chemistry Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-5361-4597
Harry WildersCrick-GSK Biomedical Linklabs, Stevenage, Hertfordshire, UK.ORCID 0009-0000-2524-2063
George S BiggsCrick-GSK Biomedical Linklabs, Stevenage, Hertfordshire, UK.ORCID 0000-0001-6526-9236
Mika KintzelThe Biological Inorganic Chemistry Laboratory, The Francis Crick Institute, London, UK.ORCID 0009-0003-1061-9931
Emma E CawoodCrick-GSK Biomedical Linklabs, Stevenage, Hertfordshire, UK.ORCID 0000-0002-2707-8022
Jonathan BaileyThe Biological Inorganic Chemistry Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0003-4088-8094
Sarah MaslenProteomics Science Technology Platform, The Francis Crick Institute, London, UK.ORCID 0000-0002-0261-2866
Yew Mun YipChemical Biology Science Technology Platform, The Francis Crick Institute, London, UK.ORCID 0000-0003-3699-8434
Mason WakleyThe Biological Inorganic Chemistry Laboratory, The Francis Crick Institute, London, UK.ORCID 0009-0009-1649-7836
Ioannis G RiziotisCrick-GSK Biomedical Linklabs, Stevenage, Hertfordshire, UK.ORCID 0000-0002-4035-1839
Thomas W ReesThe Biological Inorganic Chemistry Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-7501-3461
Joanna RedmondChemical Biology Science Technology Platform, The Francis Crick Institute, London, UK.ORCID 0000-0002-3200-4087
J Mark SkehelProteomics Science Technology Platform, The Francis Crick Institute, London, UK.ORCID 0000-0002-2432-0901
David HouseCrick-GSK Biomedical Linklabs, Stevenage, Hertfordshire, UK.ORCID 0000-0002-9635-2451
Jacob BushCrick-GSK Biomedical Linklabs, Stevenage, Hertfordshire, UK.ORCID 0000-0001-7165-0092
Jeannine HessThe Biological Inorganic Chemistry Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-5916-0728

Funding

Cancer Research UK CC2215Engineering and Physical Sciences Research Council EP/V038028/1King's College LondonMedical Research Council CC2215United Kingdom Medical Research Council CC2215Wellcome Trust CC2215
6 · The paper itself

Abstract

Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tunable geometries, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo-scaffolds (r-mS) as a class of metal complexes designed to map ligandable cysteines across the mammalian proteome. These covalent warhead-bearing metal complexes use the metal centre and ligand architecture to modulate cysteine engagement, with cysteine labelling occurring through the electrophilic chloroacetamide warhead. Using chemoproteomics, we profiled a focused r-mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome-wide targeting. Among the series screened, r-mS-2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM-binding domain of PRMT1. This interaction was validated by intact protein LC-MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π-stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo-scaffolds (r-mS) as a versatile platform for proteome-wide covalent ligand discovery and the rational development of next-generation metallodrugs.

Indexed as

Coordination ComplexesDrug DiscoveryProteomeCysteineHEK293 CellsHumansLigandsCoordination ComplexesCysteineLigandsProteomebioinorganic chemistrycysteine targetingPRMT1proteomicsreactive metallo scaffolds

Identifiers

PMID42430191
PMCPMC13573063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.